PICO Holdings Reaches Agreement With Leder Holdings
Mar 22, 2016 20:15 pm UTC| Business
LA JOLLA, Calif., March 22, 2016 -- PICO Holdings, Inc. (NasdaqGS: PICO), today announced that it has entered into an agreement with Leder Holdings, LLC and its affiliates, which collectively own approximately 1.5% of...
HealthEquity Reports Fourth Quarter and Year Ended January 31, 2016 Financial Results
Mar 22, 2016 20:15 pm UTC| Business
Highlights of the fiscal year include: Revenue of $126.8 million, an increase of 44% compared to FY15.Net income of $16.6 million, an increase of 63% compared to FY15.Net income per diluted share of $0.28 compared to...
Mercury Systems Debuts Embedded Industry’s Broadest Bandwidth OpenVPX Processor Blade
Mar 22, 2016 20:15 pm UTC| Business
CHELMSFORD, Mass., March 22, 2016 -- Mercury Systems, Inc. (NASDAQ:MRCY) (www.mrcy.com), announced the rugged OpenVPX™ Ensemble® LDS6526 processing blade that seamlessly integrates the Intel® Xeon® Processor D-1500...
Orion Marine Group Announces a Contract Award of Approximately $11 million
Mar 22, 2016 20:15 pm UTC| Business
HOUSTON, March 22, 2016 -- Orion Marine Group, Inc. (NYSE:ORN) (the "Company") a specialty construction company, today announced a contract award of approximately $11 million. The Company’s Heavy Civil Marine...
Air Methods Announces Cooperation Agreement With Voce Capital
Mar 22, 2016 20:09 pm UTC| Business
DENVER, March 22, 2016 -- Air Methods Corporation (NASDAQ:AIRM) (“Air Methods” or the “Company”), the global leader in air medical transportation, today announced that it has entered into a Cooperation Agreement with...
Insys Therapeutics, Inc. Announces 3-Month Extension of PDUFA Date for Syndros
Mar 22, 2016 20:05 pm UTC| Business
PHOENIX, March 22, 2016 -- Insys Therapeutics, Inc. (NASDAQ:INSY) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) action date for SyndrosTM...
Mar 22, 2016 20:05 pm UTC| Business
DURHAM, N.C., March 22, 2016 -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies based on the Arcelis®...